image: The distinction of Highly Cited Researchers is an important indicator for the impact of a researcher’s scientific publications, which indicates their publications rank cumulatively among the top 1% in their fields and publication years. 6,636 researchers from more than 1,200 institutions in 59 nations and regions have been recognized this year.
Credit: Insilico Medicine
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that the company's founder and CEO, Alex Zhavoronkov, PhD, again was recognized in the Highly Cited Researchers of 2024 list, revealed by global analytics company Clarivate™, following his nomination in 2022.
The distinction of Highly Cited Researchers is an important indicator for the impact of a researcher’s scientific publications, which indicates their publications rank cumulatively among the top 1% in their fields and publication years. 6,636 researchers from more than 1,200 institutions in 59 nations and regions have been recognized this year.
Dr. Zhavoronkov is highly active in publishing, with the majority of his research elucidating the algorithms and methodologies behind generative AI software and platforms for the scientific community within the biopharmaceutical industry. He also provides many best practices for applying advanced technologies, including generative AI and robotics, to early drug discovery and development. Per Google Scholar, Dr. Zhavoronkov’s publications have garnered over 16,500 citations, reflecting a total H-index of 64.
Since 2024, Dr. Zhavoronkov has published more than 40 peer-reviewed research papers, the most significant of which was published in Nature Biotechnology in March 2024 entitled “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models”. For the first time in the industry, the paper describes the entire development journey from AI algorithms to Phase II clinical trials, as well as the case study of Insilico's lead drug pipeline, ISM001-055, a potential first-in-class candidate with an AI-discovered target and AI-designed structure. Insilico recently announced positive results from a Phase IIa trial, where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after 12 weeks of dosage.
Dr. Zhavoronkov founded Insilico in 2014 and first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Since then, Insilico has integrated advanced AI technologies into its proprietary platform, Pharma.AI, which is currently a commercially available solution spanning across biology, chemistry, medicine and scientific research. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates since 2021 and has received IND clearance for 10 molecules. Insilico was recently listed in Fortune’s 50 AI innovators, which highlights the AI companies that are leading in this new phase of the technology’s adoption.
In addition to his role in Insilico, Dr Zhavoronkov serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery (11th Annual in 2023), the world's largest event on aging research in the biotechnology industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
For media inquiries, please contact media@insilicomedicine.com